Los Angeles Capital Management’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Los Angeles Capital Management’s Portfolio EIGR Stock Details EIGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,110	Closed	-$515K	–	1563
2020 Q3	$515K	Sell	2,110 -591	-22%	-$184K	﹤0.01%	1070
2020 Q2	$778K	Buy	2,701 +743	+38%	+$219K	﹤0.01%	944
2020 Q1	$399K	Buy	1,958 +957	+96%	+$305K	﹤0.01%	977
2019 Q4	$447K	Buy	1,001 +213	+27%	+$75.6K	﹤0.01%	1044
2019 Q3	$242K	Buy	788 +432	+121%	+$140K	﹤0.01%	1174
2019 Q2	$113K	Buy	+356	New	+$123K	﹤0.01%	1318

Other funds holding EIGR

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Los Angeles Capital Management's EIGR Position: Q4 2020 in Review

Los Angeles Capital Management sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2020, closing a stake of 2,110 shares — an estimated $515K sold.

Los Angeles Capital Management first reported a position in EIGR in Q2 2019 and held it in 6 quarters. The position peaked at $778K in Q2 2020. 91 funds tracked by Wall St. Rank hold EIGR as of Q4 2020.

Los Angeles Capital Management reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Los Angeles Capital Management sold 2,110 Eiger BioPharmaceuticals, Inc. shares in Q4 2020, an estimated $515K.
Los Angeles Capital Management first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2019 and held it in 6 quarters.
Los Angeles Capital Management's Eiger BioPharmaceuticals, Inc. position peaked at $778K in Q2 2020.
91 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2020.

Based on Los Angeles Capital Management's 13F filing for Q4 2020, filed 4 Feb 2021.